<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03745235</url>
  </required_header>
  <id_info>
    <org_study_id>Chauvet-Gelinier UNAFAM 2017</org_study_id>
    <nct_id>NCT03745235</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Influence of a Mindfulness-based Stress Reduction Program vs. Routine Management on Psychological Variables and Biological Markers Related to Immuno-inflammation Associated With Psychological Stress in Caregivers of Patients With Severe Psychiatric Disorders</brief_title>
  <acronym>MindInfCare</acronym>
  <official_title>A Randomized Controlled Study Comparing the Influence of a Mindfulness-based Stress Reduction Program vs. Routine Management on Psychological Variables and Biological Markers Related to Immuno-inflammation Associated With Psychological Stress in Caregivers of Patients With Severe Psychiatric Disorders.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this project is to study the influence of mindfulness meditation on&#xD;
      psychological health (stress level, affects, emotions) and physical health parameters (rate&#xD;
      of inflammatory markers in the blood, activity of white blood cells involved in&#xD;
      immuno-inflammation) in caregivers of people with psychiatric disorders. This study will&#xD;
      provide the objective scientific data required for the development of mindfulness meditation&#xD;
      programs for psychiatric caregivers.&#xD;
&#xD;
      80 participants will be randomly assigned to one of the following two groups:&#xD;
&#xD;
        -  40 participants in the &quot;Mindfulness&quot; group who will attend mindfulness meditation&#xD;
           sessions in addition to their standard follow-up&#xD;
&#xD;
        -  40 participants in the &quot;Control&quot; group who will have a standard follow-up The duration&#xD;
           of participation is 12 months and includes 3 visits and 8 mindfulness-based meditation&#xD;
           sessions for the &quot;Mindfulness&quot; group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2019</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measurement of inflammation by analysis of US-CRP blood levels</measure>
    <time_frame>Change from Baseline US-CRP blood levels at 3 and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>measurement of inflammation by analysis of IL-6 blood levels</measure>
    <time_frame>Change from Baseline IL-6 blood levels at 3 and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>measurement of lymphocyte activity Th1 Th2 Th17 Treg</measure>
    <time_frame>Change from Baseline lymphocytes activity Th1 Th2 Th17 Treg at 3 and 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Psychiatry</condition>
  <condition>Caregivers</condition>
  <condition>Mindfulness</condition>
  <arm_group>
    <arm_group_label>&quot;Mindfulness&quot; group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment as Usual</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stress reduction program based on mindfulness</intervention_name>
    <description>a two and a half hour session per week for 8 weeks</description>
    <arm_group_label>&quot;Mindfulness&quot; group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>venipunctures</intervention_name>
    <description>1 dry tube of 5 ml and 5 heparinized tubes of 6 ml taken at inclusion, at 3 months and at 12 months</description>
    <arm_group_label>&quot;Mindfulness&quot; group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>psychometric questionnaires</intervention_name>
    <description>Cohen PSS' perceived stress scale&#xD;
Beck's anxiety and depression questionnaires&#xD;
Watson's affectivity questionnaire, positive affect and negative affect schedule&#xD;
optimism questionnaire, Life Orientation Test LOT-R by Sheier and Carver&#xD;
IN-OUT DASQ dispositional affective style questionnaire</description>
    <arm_group_label>&quot;Mindfulness&quot; group</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient who has given oral consent&#xD;
&#xD;
          -  adult patient&#xD;
&#xD;
          -  a caregiver of a person with a severe psychiatric disorder (schizophrenia, recurrent&#xD;
             depression, bipolar disorder, obsessive-compulsive disorder)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  protected adult&#xD;
&#xD;
          -  patient not affiliated to the national health insurance system&#xD;
&#xD;
          -  pregnant, parturient or breastfeeding woman&#xD;
&#xD;
          -  person suffering from a severe psychiatric disorder indicating a state of&#xD;
             decompensated stress (with risk of associated biological inflammatory disturbances)&#xD;
&#xD;
          -  person suffering from an inflammatory disease (autoimmune, infectious, neoplastic,&#xD;
             cardio-vascular pathologies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Christophe CHAUVET-GELINIER</last_name>
    <phone>+33 3 80 29 37 69</phone>
    <email>jean-christophe.chauvet-gelinier@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chu Dijon Bourogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Christophe CHAUVET-GELINIER, MD</last_name>
      <phone>+33 3 80 29 37 69</phone>
      <email>jean-christophe.chauvet-gelinier@chu-dijon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emmanuel HAFFEN, MD</last_name>
      <phone>+33 3 81 21 81 54</phone>
      <email>emmanuel.haffen@univ-fcomte.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 25, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2018</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
    <mesh_term>Stress, Psychological</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

